Last Updated : January 14, 2021
Details
FilesGeneric Name:
voretigene neparvovec
Project Status:
Complete
Therapeutic Area:
Vision loss, inherited retinal dystrophy
Manufacturer:
Novartis Pharmaceuticals Canada Inc.
Call for patient/clinician input open:
Brand Name:
Luxturna
Project Line:
Reimbursement Review
Project Number:
SG0643-000
Call for patient/clinician input closed:
NOC Status at Filing:
Pre NOC
Performance Metric:
Achieved
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
For the
treatment of adult and pediatric patients with vision loss due to inherited
retinal dystrophy caused by confirmed biallelic RPE65 mutations and who have
sufficient viable retinal cells.
Submission Type:
Initial
Fee Schedule:
Schedule E
Indications:
Indicated for the treatment of adult and pediatric patients with vision loss due to inherited retinal dystrophy caused by confirmed biallelic RPE65 mutations and who have sufficient viable retinal cells.
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Final Recommendation:
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
Key Milestones2 |
|
|---|---|
| Call for patient input open | March 25, 2020 |
| Call for patient input closed | May 14, 2020 |
| Clarification:
- Patient input submission received from Canadian Council of the Blind, CNIB Foundation, Fighting Blindness Canada, Vision Loss Rehabilitation Canada (Joint Submission)
|
|
| Submission received | April 23, 2020 |
| Submission accepted | May 07, 2020 |
| Review initiated | May 08, 2020 |
| Clarification:
- Selected for CADTH/INESSS Joint Clinician Engagement |
|
| Draft CADTH review report(s) provided to sponsor for comment | July 23, 2020 |
| Deadline for sponsors comments | August 04, 2020 |
| CADTH responses on draft review report(s) provided to sponsor | September 03, 2020 |
| Expert committee meeting (initial) | September 16, 2020 |
| Draft recommendation issued to sponsor | October 22, 2020 |
| Clarification:
- CDEC recommendation held pending receipt of NOC and evaluation of the finalized submission requirements. |
|
| End of embargo period | November 05, 2020 |
| Final recommendation issued to sponsor and drug plans | November 12, 2020 |
| Final recommendation posted | November 16, 2020 |
| Deadline for sponsor to submit redaction requests on draft CADTH review report(s) | November 26, 2020 |
| CADTH review report(s) posted | January 14, 2021 |
Files
Last Updated : January 14, 2021